X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BPM 31510, the company’s lead drug candidate, acts by targeting the mitochondrial machinery and tumor microenvironment (TME) to create a metabolic shift in cancer cells, leading to cancer cell death.
Lead Product(s): Ubidecarenone,Temozolomide,Vitamin K1
Therapeutic Area: Oncology Product Name: BPM 31510
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Berg Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
The collaboration is for BPGbio’s BPM 31510 for Epidermolysis Bullosa Phase II/III trial. Debra of America will provide support to awareness, understanding, and key information towards patient recruitment and advocacy for the clinical trial.
Lead Product(s): Coenzyme Q10
Therapeutic Area: Rare Diseases and Disorders Product Name: BPM31510
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Debra of America
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 27, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
